<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303732</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00012347</org_study_id>
    <secondary_id>DUMC-6626-04-12R0</secondary_id>
    <secondary_id>CDR0000454988</secondary_id>
    <nct_id>NCT00303732</nct_id>
  </id_info>
  <brief_title>Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors</brief_title>
  <acronym>PTK/RAD</acronym>
  <official_title>PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel George, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow&#xD;
      to the tumor and by blocking some of the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and&#xD;
      everolimus and to see how well they work in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of vatalanib and everolimus in patients with&#xD;
           advanced solid tumors.&#xD;
&#xD;
        -  Determine the safety and tolerability of vatalanib and everolimus in patients with&#xD;
           advanced solid tumors.&#xD;
&#xD;
        -  Evaluate the safety and tolerability of vatalanib and everolimus at the MTD in patients&#xD;
           with metastatic renal cell carcinoma (RCC).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Describe the non dose-limiting toxic effects associated with vatalanib and everolimus.&#xD;
&#xD;
        -  Describe the pharmacokinetics of vatalanib and everolimus in patients with advanced&#xD;
           solid tumors.&#xD;
&#xD;
        -  Determine the functional extent of mTOR inhibition by changes in the phosphorylation&#xD;
           status of S6K protein in peripheral blood mononuclear cells in patients treated with&#xD;
           vatalanib and everolimus.&#xD;
&#xD;
        -  Describe any clinical responses seen in patients with metastatic RCC in a dose-expansion&#xD;
           cohort treated at the MTD.&#xD;
&#xD;
        -  Observe overall survival of RCC patients treated with vatalanib and everolimus.&#xD;
&#xD;
        -  Determine the time to progression of patients with RCC treated with vatalanib and&#xD;
           everolimus.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study followed by a phase Ib study.&#xD;
&#xD;
        -  Phase I (solid tumors): Patients receive oral vatalanib on days 1-28 and oral everolimus&#xD;
           on days 15-28 during course 1 and on days 1-28 during all subsequent courses. Treatment&#xD;
           repeats every 28 days for up to 12 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of vatalanib and everolimus until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase Ib (renal cell carcinoma only): Patients receive oral vatalanib and oral&#xD;
           everolimus at the MTD on days 1-28. Treatment repeats every 28 days for up to 12 courses&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of vatalanib and everolimus</measure>
    <time_frame>Day 1 - 28</time_frame>
    <description>Patients were evaluated on Day 1,14 and 28 for dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Duration of study treatment</time_frame>
    <description>Adverse events were assessed every 14 days for the length of the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability at the MTD in patients with metastatic renal cell carcinoma (RCC)</measure>
    <time_frame>Duration of study treatment</time_frame>
    <description>Patients were assessed for adverse events every 14 days while on study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non dose-limiting toxicity</measure>
    <time_frame>Duration of study treatment</time_frame>
    <description>Patients were assessed every 14 days for non dose-limiting toxicity while on study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 14 Cycle 1, Day 1 Cycle 2</time_frame>
    <description>Blood was drawn for PK assessment on Day 14 of Cycle 1 and Day 1 of Cycle 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the phosphorylation status of S6K protein in peripheral blood mononuclear cells</measure>
    <time_frame>Day 1 and 28</time_frame>
    <description>Samples were collected on Day 1 and at Day 28 of Cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response in patients with metastatic RCC</measure>
    <time_frame>Duration of treatment</time_frame>
    <description>patients underwent restaging studies every 2 cycles while on treatment for evidence of disease response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients with RCC</measure>
    <time_frame>Until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of patients with RCC</measure>
    <time_frame>Duration of study treatment</time_frame>
    <description>Patients were followed for evidence of disease progression as long as they remained on study drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>PTK787, RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001 (everolimus)</intervention_name>
    <arm_group_label>PTK787, RAD001</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTK787 (vatalanib)</intervention_name>
    <arm_group_label>PTK787, RAD001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor with radiographic evidence of metastatic disease&#xD;
&#xD;
               -  No standard therapy exists (phase I)&#xD;
&#xD;
               -  Unresectable or metastatic renal cell carcinoma (phase Ib)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total cholesterol &lt; 300 mg/dL&#xD;
&#xD;
          -  Triglycerides &lt; 350 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Negative proteinuria by dip stick OR total urinary protein ≤ 500 mg&#xD;
&#xD;
          -  No uncontrolled high blood pressure, history of labile hypertension, or history of&#xD;
             poor compliance with antihypertensive regimen&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No symptomatic congestive heart failure (New York Heart Association class III or IV&#xD;
             heart disease)&#xD;
&#xD;
          -  No uncontrolled serious cardiac arrhythmia (symptomatic supraventricular tachycardia&#xD;
             or any ventricular tachycardia/fibrillation)&#xD;
&#xD;
          -  No myocardial infarction in the past 6 months&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the&#xD;
             lung&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No uncontrolled hyperlipidemia&#xD;
&#xD;
          -  No chronic renal disease&#xD;
&#xD;
          -  No acute or chronic liver disease (e.g., hepatitis or cirrhosis)&#xD;
&#xD;
          -  No impaired gastrointestinal (GI) function OR GI disease that may significantly alter&#xD;
             the absorption of vatalanib or everolimus, including any of the following:&#xD;
&#xD;
               -  Ulcerative disease&#xD;
&#xD;
               -  Uncontrolled nausea and vomiting with solid food&#xD;
&#xD;
               -  Watery diarrhea &gt; 5 times daily&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Bowel obstruction&#xD;
&#xD;
               -  Inability to swallow the tablets&#xD;
&#xD;
          -  No confirmed HIV infection&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent severe and/or uncontrolled medical condition that would preclude&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior antivascular endothelial growth factor therapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery* (laparotomy)&#xD;
&#xD;
          -  More than 2 weeks since prior minor surgery*&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)&#xD;
&#xD;
          -  More than 6 weeks since prior antibody therapy&#xD;
&#xD;
          -  More than 2 weeks since prior biologic/immunotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior limited-field radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior full-field radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  Prior transfusions allowed provided blood counts are stable for &gt; 2 weeks&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
          -  No concurrent warfarin or similar oral anticoagulants that are metabolized by the&#xD;
             cytochrome P450 system&#xD;
&#xD;
               -  Heparin and low molecular weight heparin allowed NOTE: *Insertion of a vascular&#xD;
                  access device is not considered major or minor surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Speca JC, Mears AL, Creel PA, et al.: Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. [Abstract] J Clin Oncol 25 (Suppl 18): A-5039, 244s, 2007.</citation>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Daniel George, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

